Status:
UNKNOWN
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborating Sponsors:
Second Affiliated Hospital of Xi'an Jiaotong University
Tang-Du Hospital
Conditions:
Sepsis Syndrome
MODS
Eligibility:
All Genders
18-84 years
Brief Summary
Continuous renal replacement therapy is widely used in intensive care medicine, which is known as an alternative therapy to save injured kidney . Anticoagulation is an important part of this therapy. ...
Detailed Description
CRRT, the continuous renal replacement therapy, is widely applied in the field of intensive care medicine. This technology is known as an alternative therapy to save injured kidney with advantages of ...
Eligibility Criteria
Inclusion
- Critically ill patients admitted to ICU
- ICU patients requiring further CRRT due to renal or non-renal indications
- signed informed consent
Exclusion
- The hospitalization stay of ICU is less than 24 hours.
- The case data are incomplete.
- age\<18 and ≥85
- patients suffering from metal illness or unable to cooperate for some certain reasons
- allergic to NM or Pharmaceutical excipient or extracorporeal circuit consumables
- preparing for pregnancy/pregnant/ during lactation period
- patients or their agents refuse to sign the informed consent form or participate in another clinical trial
- non-compliant, lost visit or other situations that patients are unsuitable for selection determined by researchers
Key Trial Info
Start Date :
May 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 3 2024
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT05382078
Start Date
May 31 2022
End Date
May 3 2024
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xian JiaotongUniversity
Xi'an, Shaanxi, China, 710061